Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer

The Journal of Clinical Investigation
Na ZhaoXi Chen

Abstract

The unfolded protein response (UPR) is a cellular homeostatic mechanism that is activated in many human cancers and plays pivotal roles in tumor progression and therapy resistance. However, the molecular mechanisms for UPR activation and regulation in cancer cells remain elusive. Here, we show that oncogenic MYC regulates the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1) branch of the UPR in breast cancer via multiple mechanisms. We found that MYC directly controls IRE1 transcription by binding to its promoter and enhancer. Furthermore, MYC forms a transcriptional complex with XBP1, a target of IRE1, and enhances its transcriptional activity. Importantly, we demonstrate that XBP1 is a synthetic lethal partner of MYC. Silencing of XBP1 selectively blocked the growth of MYC-hyperactivated cells. Pharmacological inhibition of IRE1 RNase activity with small molecule inhibitor 8866 selectively restrained the MYC-overexpressing tumor growth in vivo in a cohort of preclinical patient-derived xenograft models and genetically engineered mouse models. Strikingly, 8866 substantially enhanced the efficacy of docetaxel chemotherapy, resulting in rapid regression of MYC-overexpressing tumors. Collectively, these data esta...Continue Reading

References

Oct 14, 2000·Annual Review of Cell and Developmental Biology·C GrandoriR N Eisenman
Apr 23, 2004·The EMBO Journal·Masayoshi YadaKeiichi I Nakayama
May 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·Markus WelckerBruce E Clurman
Jul 11, 2006·Science·Julie Hollien, Jonathan S Weissman
Jun 15, 2007·Nature Reviews. Molecular Cell Biology·David Ron, Peter Walter
Jun 17, 2008·Science·Ann-Hwee LeeLaurie H Glimcher
Jun 28, 2008·Contemporary Clinical Trials·Robert H LylesCarlton R Cooper
Dec 17, 2008·Nature·Alexei V KorennykhPeter Walter
Feb 19, 2009·Molecular and Cellular Biology·Matthew Bechard, Stephen Dalton
Sep 30, 2010·Nature Reviews. Clinical Oncology·Lisa CareyLuca Gianni
May 13, 2011·The New England Journal of Medicine·Scott C HowardChing-Hon Pui
Jun 3, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jason I HerschkowitzJeffrey M Rosen
Feb 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Benedict C S CrossHeather P Harding
Mar 21, 2012·The Journal of Experimental Medicine·Dai HoriuchiAndrei Goga
Apr 3, 2012·Cell·Chi V Dang
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 2, 2012·Cell·Charles Y LinRichard A Young
Nov 13, 2012·The Journal of Clinical Investigation·Lori S HartConstantinos Koumenis
May 3, 2014·The Journal of Clinical Investigation·Thomas CondamineDmitry I Gabrilovich
May 9, 2014·The Journal of Clinical Investigation·Chih-Hang Anthony TangChih-Chi Andrew Hu
May 16, 2014·Cancer Cell·Hanna J ClarkeStefan J Marciniak
Aug 26, 2014·Nature Reviews. Cancer·Miao Wang, Randal J Kaufman
Oct 18, 2014·Nature Chemical Biology·Dustin J Maly, Feroz R Papa
Apr 7, 2015·The Journal of Clinical Investigation·Sorin V FedelesAnn-Hwee Lee

❮ Previous
Next ❯

Citations

Oct 13, 2018·Thoracic Cancer·Miao Chen, Songbo Xie
Feb 6, 2019·The FEBS Journal·Ahmad AbdullahPalaniyandi Ravanan
May 2, 2019·Molecular Carcinogenesis·Fiona ChalmersAdam B Glick
Nov 20, 2019·Cancers·Su Min Nam, Young Joo Jeon
Apr 21, 2020·EMBO Molecular Medicine·Tingting ZhangXia Sheng
May 24, 2020·The FEBS Journal·Dimitrios DoultsinosLeif A Eriksson
Sep 27, 2018·Cancers·Eoghan P McGrathAfshin Samali
Jan 27, 2019·Nature Communications·Xia ShengFahri Saatcioglu
Aug 28, 2020·Frontiers in Oncology·Longyong XuXi Chen
Dec 24, 2019·Frontiers in Immunology·Olivia I Coleman, Dirk Haller
Jul 20, 2019·Science·Sahil ChopraJuan R Cubillos-Ruiz
Jul 20, 2019·Nature Chemical Biology·Claudio HetzJohn B Patterson
Sep 8, 2019·International Journal of Molecular Sciences·Natalia SiweckaIreneusz Majsterek
Aug 24, 2018·International Journal of Molecular Sciences·Nuria Garcia-CarboneroJesus Garcia-Foncillas
Oct 20, 2020·British Journal of Cancer·Christian SchneeweisGünter Schneider
Oct 26, 2020·Molecular Oncology·Katharina LankesMatthias Wirth
Nov 21, 2020·Nature Reviews. Cancer·Xi Chen, Juan R Cubillos-Ruiz
Dec 4, 2020·Journal of Hematology & Oncology·Tianming ZhaoHui Zeng
Jan 11, 2021·Trends in Pharmacological Sciences·Dexter Kai Hao ThngEdward Kai-Hua Chow
Feb 11, 2021·Biomedicines·Natalia SiweckaIreneusz Majsterek
Mar 5, 2021·Frontiers of Medicine·Chen WangYing Gu
Mar 12, 2021·Signal Transduction and Targeted Therapy·Chen WangWendong Huang
Mar 19, 2021·Cellular & Molecular Biology Letters·Sylwia BartoszewskaRafal Bartoszewski
Sep 12, 2020·Journal of Medicinal Chemistry·Christian Gampe, Vishal A Verma
Mar 1, 2020·The American Journal of Pathology·Scott A Oakes

❮ Previous
Next ❯

Methods Mentioned

BETA
ChIP
PCR
xenograft
glycosylation
pull-down
fluorescence resonance energy transfer
ubiquitination
protein modification
nuclear translocation
transfection

Software Mentioned

GraphPad Prism
Aperio IHC
QuantStudio
FlowJo
GraphPad

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.